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ABSTRACT
Motivation: Analyses of EST data show that alternative splicing is
much more widespread than once thought. The advent of exon and
tiling microarrays means that researchers now have the capacity to
experimentally measure alternative splicing on a genomewide level.
New methods are needed to analyze the data from these arrays.
Results: We present a method, ﬁnding isoforms using robust
multichip analysis (FIRMA), for detecting differential alternative
splicing in exon array data. FIRMA has been developed for Affymetrix
exon arrays, but could in principle be extended to other exon arrays,
tiling arrays or splice junction arrays. We have evaluated the method
using simulated data, and have also applied it to two datasets: a
panel of 11 human tissues and a set of 10 pairs of matched normal
and tumor colon tissue. FIRMA is able to detect exons in several
genes conﬁrmed by reverse transcriptase PCR.
Availability: R code implementing our methods is contributed to the
package aroma.affymetrix.
Contact: epurdom@stat.berkeley.edu
Supplementary information: Supplementary data are available at
Bioinformatics online.
1 INTRODUCTION
Alternative splicing is thought to have several roles in complex
organisms, primarily in increasing protein diversity (Maniatis and
Tasic, 2002). It can affect the intracellular localization, binding
properties or stability of a protein, or regulate its expression via
nonsense-mediateddecay(NMD)(Stammetal.,2005).Theseevents
usually occur in a regulated manner, but if an aberrant splicing event
occurs,itcanbecausativefor,orsymptomaticof,disease.Morethan
15% of heritable human diseases are known to be associated with
mutations in splice sites or in splicing regulatory elements (Matlin
et al., 2005). In particular, aberrant pre–mRNA splicing events are
known to be implicated in several types of cancer (Brinkman, 2004;
Venables, 2004).
Previously thought to be a relatively uncommon phenomenon,
alternative splicing has recently been shown to be widespread
∗
To whom correspondence should be addressed.
throughout the genome. Analyses of data on human expressed
sequence tags (ESTs) give estimated lower bounds between
35% and 59% for the proportion of genes which have at least
one splice variant (Modrek and Lee, 2002). The frequency of
functional alternative splicing events is probably lower than
this. Several groups have searched for alternative splicing events
conserved between human and mouse, and their results suggest
that the proportion of functionally alternatively spliced genes is
∼10% (Sorek et al., 2004; Sugnet et al., 2004; Yeo et al., 2005).
Aweakness of all EST-based methods is that they are biased towards
genes which have greater EST coverage (Modrek and Lee, 2002).
Several kinds of alternative splicing have been observed (see
Black, 2003, for a recent review). The most common form is
skipping or inclusion of one or more ‘cassette’ exons (roughly
40–50% of cases based on bioinformatic evidence (Clark and
Thanaraj, 2002; Sugnet et al., 2004), these being exons which are
whollypresentinsometranscripts,andwhollyabsentinsomeothers.
Alternatively,mutuallyexclusivecassetteexonusagecantakeplace;
e.g. exon A or exon B forms part of the transcript, but never A
and B together (more generally, multiple exons can exhibit mutual
exclusivity). Usage of alternative 3  or 5  splice sites can result in
shortening or lengthening of an exon. Other types of alternative
splicing that have been observed are alternative promoter usage,
alternative polyadenylation sites and intron retention. Additionally,
any combination of the above may occur in an alternatively spliced
transcript (Black, 2003).
Skipping or inclusion of internal cassette exons is the most
common kind of alternative splicing, and possibly the easiest to
detect and verify. For this reason, we have focused on identifying
speciﬁcexonsshowingpatternsofdifferentialalternativeexpression
and have not approached the problem of reconstructing more
complicated transcript patterns.
Our algorithm FIRMA has been developed for analyzing the
Affymetrix exon array, Santa Clara, California, USA, which queries
the expression level of well annotated and as well as predicted
exons. In brief, FIRMA scores each exon as to whether its probes
systematically deviate from the expected gene expression level.
With a small number of probes per exon (four or less), this is a
challenging microarray platform to analyze—such deviations can
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come from a myriad of biological and technical factors unrelated
to alternative splicing. We show that FIRMA performs well in
detecting exon-speciﬁc changes in expression and therefore can
contribute substantially to the detection of regulated alternative
splicing. Of course a single scoring method can only be one step
in the analysis, and any results must be evaluated in the light of
these other complications.
2 MATERIALS
The GeneChip Human Exon 1.0 ST(sense target) array is a whole-genome
array, containing over 1.4 million probesets of up to four perfect match (PM)
probes each, spread across exons from all known genes, plus a number of
additional regions based on other annotation sources, including GENSCAN
predictions and ESTs from dbEST. In the design phase, sequences from all
the annotation sources were mapped to the July 2003 version of the human
genome (UCSC hg16, NCBI 34). Regions which had some evidence from
one or more sources for being transcribed were divided into probe selection
regions (PSR) according to the presence of canonical splice sites, CDS start
and stop positions or polyadenylation sites. Probes were then selected from
within PSRs >25bp in length. Each PSR corresponds to a probeset, which
generally contains four possibly overlapping probes (sometimes fewer).
About a quarter of the probesets are based solely on EST evidence, while
another quarter are based solely on GENSCAN predictions (GeneChip
Exon Array Design Technical Note, Affymetrix).
The array contains only PM probes, with a small number of generic
mismatch probes for the purposes of background correction. There are no
probes which span exon–exon junctions.
Association of probesets with genes is not made at design time. Instead,
these‘main-design’probesetsareannotatedafterwards,usingtheiralignment
to the genome (Exon Probeset Annotations Whitepaper, Affymetrix). This
process has been undertaken by Affymetrix, ﬁrst for NCBI Build 34 of the
genome, and more recently for Build 35. The result is that each probeset is
assigned to a ‘transcript cluster’, and also has an annotation quality indicator
associated with it.
3 ALGORITHM
Our method is developed to evaluate levels of alternative splicing
for the situation where there are no replicates nor pre-deﬁned groups
in the samples or alternative splicing does not consistently follow
the groupings that exist. The second situation can be quite common,
for example in disease versus normal where alternative splicing may
exist in only a proportion of the diseased samples for a given gene.
Alternatively there may be groupings, such as tissue type, where
patterns of alternative splicing are shared amongst several tissue
types, but the tissue types that share a similar splicing pattern may
be different in different genes. For this reason, our algorithm is
sample-by-exon speciﬁc: each exon and sample pairing is given a
score that is comparable across either samples, genes or exons.
3.1 Alternative splicing detection method
The two major steps in our method are estimation of the expression
levels of each gene, using the robust multichip analysis (RMA)
approach (Irizarry et al., 2003), and detection of alternative splicing
using a suitably deﬁned score from auxiliary information from the
estimation step. We call the combined approach ﬁnding isoforms
using robust multichip analysis (FIRMA).
RMA itself involves three steps: background correction,
normalization and summarization of the probe-level data (Irizarry
et al., 2003). The following discussion assumes that the ﬁrst two
steps have already been performed.
We extract the normalized probe-level data for the probes
belongingtoatranscriptcluster.Theexactsetofprobesetswhichare
used may depend on the aim of the experiment. If this is detection
of novel exons, then all probesets might be used (though note the
problems with non-expressed regions mentioned in the Discussion).
If alternative splicing of well-annotated exons is of more interest,
then the analysis might be restricted to well-annotated probesets. In
the development below, we will refer to ‘exons’, though in fact the
analysis is done on probesets, which usually coincide with an exon.
The ﬁnal step in RMA is to estimate the gene expression level of
each sample by ﬁtting the following additive model for each gene:
log2(PMik)=ci+pk+ ik, (1)
where ci is the chip effect (expression level) for chip i, pk is the
probe effect for probe k, (and which can be interpreted as a relative
probe afﬁnity if we use the constraint
 
kpk =0), and log2(PM)ik is
the log (base 2) of the background-corrected, normalized PM signal
for probe k on chip i (Irizarry et al., 2003). The model is ﬁtted using
iteratively reweighted least squares (IRLS) (Marazzi, 1993).
Fortheexonarray,wecanconsideramoregeneraladditivemodel
which includes the possibility of alternative splicing or different
levels of expression per exon,
log2(PMijk(j))=ci+ej+dij+pk(j)+ ijk(j), (2)
where (again assuming a zero-sum constraint for these parameters)
ej is the relative change in exon expression for exon j, dij is the
interaction between chip and exon giving the relative change for
sample i in exon j, and pk( j) is the nested relative probe effect for
the k-th probe in exon j.
The parameter dij indicates the discrepancy of a given sample in
exonj fromtheexpectedexpressionforthatexon.Itislargevaluesof
this parameter that indicate differential alternative splicing. Rather
than ﬁt this extended model and estimate dij explicitly, we propose
to ﬁt the standard RMA model in (1) for the exon array. If there is
a large discrepancy in some samples (a large dij) then we will see
this as large residuals for the probes for that sample in that exon.
Inthisway,weframetheproblemofdetectingalternativesplicing
as a problem of outlier detection, rather than estimation of an
interaction effect. By robustly ﬁtting without the term dij we avoid
the additional noise that would be added to all of our parameter
estimates, since there are at most four observations to estimate this
term. We do assume, however, limited levels of alternative splicing
so that the other terms in the model are still well estimated with our
robust estimation procedure even though dij is excluded from the
model.
Based on this logic, let
rijk =yijk−ˆ ci−ˆ pk,
be the residuals from ﬁtting the standard model in Equation (1).
Then for each exon j and sample i, a summary score based on the
four residuals from exon j and sample i gives a measure of the
discrepancy dij in the expression of the exon in that sample.
Any number of scoring functions could be used. The most
obvious choice is the mean. More robust alternatives would be
the median residual, the lower quartile or even the smallest of the
absolute residuals. We considered these various options in scoring.
Ultimately, we determined that the median of the residuals in an
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exon gave the best tradeoff between sensitivity to the size and sign
of the residuals and robustness to the small number of probes (see
Section 4, below, for simulation results that compare the scores).
This gives us a ﬁnal score statistic,
Fij=median
k∈exon j
rijk/s.
Theestimateofstandarderror,s,isestimatedbythemedianabsolute
deviation (MAD) of the residuals and helps to make the scores
comparable between different genes.
Note that the term ej is not estimated separately if we ﬁt the
standard RMAmodel—it will be absorbed into the probe estimates.
Large values of the parameter ej can also indicate alternative
splicing, but only where the overall shift in level of expression of
the exon is shared amongst all of the samples. The FIRMA scores
could be adjusted to include this information but so far we are not
convinced that the data is clean enough for the beneﬁts to outweigh
the additional noise. Often a shift in expression level will come
from the many possible complications in the annotation or the probe
deﬁnitions in the array, and with at most four probes it will be
difﬁculttoisolatethebiologicalsignalfromthesetechnicalproblems
(see Section 5, below). Since most experiments will be designed to
ﬁnd differential splicing amongst the samples included, rather than
shared effects, this should not be a problem. See Supplementary
MaterialsforanillustrationofthiseffectontheUNRgenediscussed
subsequently.
Because existing bioconductor functions used to analyze
GeneChip data require all the data to be in memory at once,
we could not use them because of the size of the Human
Exon array. Instead we implemented the FIRMA algorithm in the
aroma.affymetrix package for large datasets which makes use
of persistent memory aroma.affymetrix. See Supplementary
Materials for more information.
3.2 Other splicing detection methods
Numerous other alternative splicing detection algorithms have been
proposed. Many of the techniques extended linear models similar to
our motivating model in Equation (2).
Affymetrix proposes several techniques based on their proposal
for ﬁtting gene and exon expression levels (Alternative Transcript
Detection Whitepaper, Affymetrix). Their general approach differs
from our RMAapproach in two ways. First they use their algorithm
PLIER (rather than IRLS) to robustly ﬁt the standard linear model in
(1).Secondtheyproposetwoseparateestimationsusingthestandard
linear model in Equation (1): ﬁrst ﬁt the standard model using all
of the probes in the gene to get an estimate of the gene intensity
for each sample (ˆ Gi) and then ﬁt the same model but only on the
probes in a particular exon to get an estimate of the exon intensity
in each sample (ˆ Eij). We can interpret the estimates in terms of
our general model (2). We can see that log( ˆ Gi) is an estimate of
ci and log(ˆ Eij) is an estimate of ci+ej+dij. Affymetrix deﬁnes the
normalized exon intensity as NIij= ˆ Eij/ˆ Gi, which implies that the
log of the normalized exon intensity (logNI) estimates ej+dij.
While the normalized exon intensity gives a sample-by-exon
score,Affymetrix does not propose the normalized exon intensity as
a score for alternative splicing. Instead they propose statistics that
give a score per exon: the pattern-based correlation (PAC) statistic
and microarray detection of alternative splicing (MIDAS). PAC is
the correlation across samples of ˆ Eij and ˆ Gi, PACj=cori(ˆ Eij, ˆ Gi).
MIDAS is an ANOVA test for differences in the group means
of the logNI. MIDAS obviously requires predeﬁned groupings or
replicates of the samples.
From the deﬁnition, it is clear that PAC works best when there
areenoughdifferentiallysplicedsamplestosigniﬁcantlyweakenthe
correlation between gene and exon expression levels. In general, we
found the PAC to be a weak measure of alternative splicing for an
exon, both in simulations and in datasets we examined, probably
because only a small proportion of samples were differentially
spliced in any gene.
Other methods are related to alternative splicing but address
different questions or platforms. DECONV(Wang et al., 2003)i sa n
algorithm which attempts to estimate the relative concentrations of
known isoforms by maximum likelihood methods.ANOSVA(Cline
etal.,2004)assumesreplicatedsamplesandﬁtsalloftheparameters
in the exon model in Equation (2) and then tests for dij that are non-
zero. Other methods developed recently are the correlation-based
method of Le et al. (2004), and the Bayesian method (GenASAP) of
Shaietal.(2006),whoattempttoestimaterelativeexpressionoftwo
isoforms in the same sample, a difﬁcult problem. Their algorithm
was developed for a custom array containing splice junction probes,
and gives good agreement with RT-PCR assays undertaken for
validation purposes.
4 IMPLEMENTATION
4.1 Simulation study
To test the scoring methods discussed in Section 3.1, we devised
a simulation model. All analyses were done in R (R Development
Core Team, 2006). Synthetic data were generated and our FIRMA
scores, as well as Affymetrix’s PAC and NI scores, were calculated
fromthesedata.WedidnottestMIDASorANOSVA,asbothrequire
replicated samples, and our aim here is to detect alternative splicing
without replication.
Data are simulated according to the following model:
yij=log2(Bj+Iij×2(ci+pj))+ ij, (3)
with yij the log2(PM) for chip i and probe j. The additive
background, Bj, is modeled as a log-normal variable, the chip effect
ci as a normal variable, and the probe afﬁnity pj and the residuals  ij
as mean-zero normal variables. The indicator variable Iij is 1 when
probe j is expressed on chip i, and 0 otherwise.
This model features additive background, multiplicative noise,
and probe-speciﬁc afﬁnities. We chose values for the simulation
parameters by obtaining rough estimates of ‘typical’ values from
real data We simulated a gene with 10 exons (four probes per exon)
with six variants, each one with one fewer exon than the preceding
one. When a variant was included in the data, we set Iij=0 for
all four probes belonging to the dropped exon. See Supplementary
Materials for more details regarding the implementation.
500 simulations were performed for each of two different values
of the mean chip effect (7 and 10) and four different probabilities
of including a splice isoform (P=0.1, 0.3, 0.5, 0.8), i.e. eight cases
in total. The two values of the mean chip effect were chosen to
mimic differing scenarios—one where the expression is close to
background, and one where it is far above background. Forty chips
were simulated for each run, and each was randomly selected to
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have either the full transcript or one of the six variants (the variant
to be included was then also chosen randomly).
Four different summaries of the residuals mentioned earlier were
testedonthesimulateddata:themeanandthemedianoftheresiduals
and the minimum and the lower quartile of the absolute residuals
belonging to a probe in the exon. We also calculated a version of
Affymetrix’s logNI, with estimates log(ˆ Eij) and log( ˆ Gi) given by
the IRLS estimation used by RMA rather than PLIER for ease of
comparison. These are all single-sample methods, i.e. they aim to
detect alternative splicing in each exon for each sample.
We note the logNI as a single-sample technique which has
some possible advantages in our simulations. In particular, if the
proportion of samples showing alternative splicing is high within
an exon (say in the majority of samples), the high residuals will be
found not in those samples classiﬁed by the simulation as spliced
out, but rather the complementary set of samples; in such cases,
the FIRMA values will call the wrong set of samples spliced. The
logNI index, as we mentioned earlier, will also estimate which
samples are different from the overall gene expression; thus for high
proportions of splicing in the simulation, it may have an advantage
in calling individual samples spliced. In reality, which samples are
considered‘spliced’insuchasituationwouldbegenerallyaquestion
of deﬁnition.
We also did some brief comparison of all-sample methods—
methods that seek to pinpoint exons with alternative splicing,
but do not determine in which samples the exon is alternatively
spliced. The PAC is an example of such a method, as is the standard
deviation (SD) of the logNI. As a comparison, we tried different
summaries of our FIRMA score (based on the median residual):
the maximum FIRMA score among the samples, the fourth largest
among samples, and the SD across samples.
Table 1 summarizes the area under the Receiver Operating
Characteristic (ROC) curve created using the single-sample
and all-sample methods; note that the ROC curves are not
comparablebetweenthetwodifferentapproachesbecausetheevents
being classiﬁed are entirely different (with different underlying
probabilities).There are several observations to make aboutTable 1.
In the single-sample methods, the variants of the FIRMA scores
perform better than the logNI, despite its possible advantages in
the simulation study when there are high levels of splicing. For
all-sample methods, the SD of either the FIRMA scores or the
logNI scores seems to be competitive and both are consistently well
behaved across different probabilities of splicing and expression
level.
4.2 Application to real data
We used for our analyses two sets of biological samples evaluated
on the Human Exon 1.0 ST chip publicly available fromAffymetrix
http://www.affymetrix.com/.The ﬁrst is a set of tissues consisting of
11 different tissues (breast, cerebellum, heart, kidney, liver, muscle,
pancreas, prostate, spleen, testes and thyroid) with three technical
replicates of each. The second is a set of 10 matched normal-tumor
colon cancer pairs analyzed by Gardina et al. (2006) (20 arrays).
We evaluated the performance of the algorithm on genes
validated to have alternative splicing. This allowed us to determine,
case-by-case, whether the algorithm gives sensible answers. We
performed genome-wide searches for high scoring probesets to give
perspective on how the scores for these validated genes compared
to other genes on the array. In addition, our genome-wide search
Table 1. Area under the ROC curve for the cases described in the text
Mean expr=7 Mean expr=10
Method 0.1 0.3 0.5 0.8 0.1 0.3 0.5 0.8
S
i
n
g
l
e
-
S
a
m
p
l
e
Median 0.94 0.92 0.89 0.78 0.99 0.98 0.96 0.84
Mean 0.97 0.95 0.93 0.83 0.99 0.99 0.97 0.86
LQ 0.93 0.90 0.86 0.74 0.98 0.97 0.94 0.80
Min 0.84 0.81 0.77 0.67 0.94 0.92 0.87 0.71
NI 0.86 0.85 0.83 0.78 0.97 0.96 0.95 0.88
A
l
l
-
S
a
m
p
l
e
FIRMA



Max 0.87 0.80 0.73 0.72 0.92 0.82 0.73 0.75
4th 0.66 0.82 0.84 0.86 0.70 0.84 0.86 0.90
SD 0.85 0.84 0.80 0.82 0.92 0.87 0.83 0.87
Affymetrix
 
SD(NI) 0.86 0.84 0.81 0.82 0.93 0.87 0.85 0.89
PAC 0.39 0.50 0.54 0.55 0.41 0.50 0.56 0.60
Thenumbersinthetableheaderindicatetheprobabilityofincludingavariantisoformin
any given sample. The largest area under the curve value for each probability (column)
noted in bold font for both the single-sample and all-sample methods. Bold values
highlight the largest (best) AUC in each column.
gave us candidate probesets—examples of probesets that would be
found de novo by our algorithm—to further evaluate the behavior of
the algorithm. However, such a genome-wide search creates a large
number of additional questions; for example, what criteria should be
used, and how should we exclude poorly behaving genes or exons,
and how to evaluate the results with only a very limited knowledge
of the truth. For the purposes of this article, we chose to focus on
the question of deﬁning a good initial metric to identify alternative
splicing within a gene.
Our analysis used the procedure outlined in Section 3.1
and implemented in aroma.affymetrix: the chips were
individually background corrected and then jointly quantile
normalized (using all of the main-design probes) and then the
standard RMA model in (1) was ﬁt (per gene) using the gene
deﬁnitions from Ensembl (Hubbard et al., 2007). This means only
the 332532 probesets that mapped to the Ensembl annotation were
retained, which constituted 23385 gene deﬁnitions. FIRMA scores
werecalculatedforeachprobesetandsamplefromtheresidualsfrom
these ﬁts. Our background correction is the standard RMAand does
not make use of the control probes, but rather the main-design PM
probes.Toaidinevaluationofthealgorithmweimplementedsimple
ﬁltering of low-expressed probesets (see Supplementary Materials
for details).As has been noted in previous work (e.g. Gardina et al.,
2006), non-expressed probesets induce false positives on the array:
their expression is merely background noise and thus no longer
tracks the expression of the gene.
4.2.1 Panel of tissue samples FIRMA was applied to the tissue
sample arrays from Affymetrix. Speciﬁcally, we asked whether
FIRMA could predict muscle speciﬁcity for a group of exons
previously validated by RT-PCR as being enriched in heart and
skeletal muscle (Das et al., 2007). Here we focused on the 11
exons which were contained in our Ensembl mapping. As shown
in Figure 1, FIRMA successfully predicted most of the relevant
probesetstobemuscle-enriched.Theobservedvariabilityinmuscle-
enrichment indicated by the color scale is to be expected, since
the original RT-PCR validations showed considerable variation in
muscle-speciﬁcity. Moreover, the predictions of muscle-speciﬁcity
made in that study utilized a different set of tissue data that
was heavily weighted towards brain. In particular based on the
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Fig. 1. FIRMA scores represented by color scale for all 11 of the validated
probesets (left of dividing line) as well as 15 additional top scoring probesets
(right of dividing line). Two validated genes (UNR and ITGB1) also ranked
high enough to be included in the top 15 candidate genes and their labels are
coloredingreentonotethis.Notethatthecolorscaleisnotevenlyspacedbut
rather based on percentiles of all FIRMAscores in all non-ﬁltered probesets
and samples.
PCR data (Das et al., 2007), CACNB1—which demonstrated no
obvious evidence of splicing in the FIRMA analysis—might better
have been classiﬁed as brain-depleted rather than muscle-enriched.
WeconcludethatFIRMAwaseffectiveasasample-speciﬁcmeasure
of splicing in this control study.
We also performed a genome-wide search for high-scoring
probesets as a comparison to this set of probesets with conﬁrmed
splicing. To provide better comparison to the validated genes, we
searched for probesets with enriched expression value in the muscle
or heart tissues, as compared to other tissues. We scored each
probeset by ﬁnding the minimum FIRMA score in each of the
two tissue groups and then took the maximum (see Supplementary
Materials for details); this created an all-sample score, to use our
terminology from above. This score ensured that at least one of the
two tissues had uniformly high FIRMAscores in all three replicates.
As we mentioned above, there are many issues in a genome-wide
search which we do not treat; this technique was a simple way to
get additional candidates for comparison.
In Figure 1 we show the FIRMA scores in each of the tissue
samples for the 11 conﬁrmed probesets plus 15 additional top
candidate genes found de novo by FIRMA. Our FIRMA scores
did reasonably well in determining alternative splicing, given the
evidence available on the exon array. In all cases, except CACNB1,
the FIRMA scores of the muscle tissues are decidedly positive,
indicating enrichment. UNR, in particular, shows extremely high
scores in the muscle and heart and much smaller scores in the other
tissues; indeed UNR also has the highest score in our genome-wide
scan. We show the example of UNR in more detail in Figure 3.
Other tissues, in particular thyroid, also demonstrate high FIRMA
scores in many of the probesets, demonstrating the ﬂexibility
of not pre-deﬁning the groups in advance. The genes LRRFIP1,
LRRFIP2, SVIL and DYSF have only modest FIRMA scores in
their muscle and heart tissues relative to those of the other genes.
CACNB1 shows no marked FIRMA scores in any of its tissues.
Fig. 2. Boxplots of the FIRMA scores for all probesets in the Ensembl
annotation mapping (332532 probesets) for each of the 33 arrays. The
boxplots of muscle and heart tissues are colored red. The scores for the
probesets of a few of the validated genes are mapped on top of the boxplots
(see legend in graph).
(a) Log-Expression
(b) Firma Scores
Fig. 3. Analysis for UNR: (a) Log expression values for UNR, with the
estimated probe effect subtracted off (log(PM)ijk−ˆ pk). Probes are plotted
alongthex-axis,withgreyverticallinesseparatingtheprobesets;eachplotted
line corresponds to an array. (b) UNR FIRMA scores for all probesets of
UNR, aligned to match (a); the color scale is the same as in Figure 1. In both
plots, the lines and labels of muscle and heart tissues are colored red and
those of thyroid colored yellow.
These results are consistent with their performance on the array
based on visual inspection. In Figure 2 we show the scores of a few
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of these probesets as compared to the scores of all probesets used
in our analysis.
On the other hand some probesets show a general spread of
FIRMA scores across samples with lower relative scores, despite
showing evidence of splicing on visual inspection of the data.
Looking closely at the data and residuals for all of the genes
(supplied in the Supplementary Materials) we see that this is most
common in two related types of cases: (1) when there is a wide
spectrum of the level at which the tissues show alternative splicing
and (2) when there is a relatively separated level of expression for
alternatively spliced arrays, but there are more tissues than just heart
and muscle which share in the alternative splicing. In both cases the
residuals for many (if not most) of the samples will be large in that
probeset, not just the enriched samples, though obviously the scores
will have different signs. One such example is the gene ABLIM1.
Here, there is an increase in expression of heart and muscle tissue,
but also a relatively similar level of increase in thyroid and prostate.
The remaining tissues show some variable change in expression in
this probeset, all of which is lower than the enriched tissues and
some of which is lower than their overall gene expression. As a
result, both the high- and low-expressed tissues for this probeset
have large residuals, but none have extremely large residuals despite
the large increase in expression (see Supplementary Materials for
ﬁgures demonstrating this behavior). The scores could be adjusted
to be more informative as to which arrays are different by either
explicitly comparing to the overall estimated gene expression or
arbitrarily deﬁning a different point of comparison than the middle
(zero-level) residual; however, this could also add a great deal of
noise and remains an area of further exploration. Despite these
drawbacks, ABLIM1 still ranks in the top 100 probesets in our
genome-wide scan (rank=63).
To evaluate the new muscle-speciﬁc probesets predicted by
FIRMA, we used the UCSC genome browser to identify and
examine the exons in which the probesets reside. The majority
of these candidates have properties similar to the known muscle-
enriched exons deﬁned in Das et al. (2007): they are alternatively
spliced, relatively short exons that are evolutionarily conserved
among vertebrates, and they possess some of the putative splicing
regulatory elements, located in ﬂanking introns, known to be
over-represented near other muscle-enriched exons. Two candidate
probesets from SLC25A3 and CAPZB also were identiﬁed in the
muscle-enrichment screen of Das et al., though not selected for their
RT-PCR screen. These properties strongly suggest that FIRMA has
successfully identiﬁed a number of new muscle-speciﬁc alternative
exons.
Using the package biomaRt in R (Durinck et al., 2005), we
classiﬁed all of the probesets as to whether they were contained
in all the transcripts for that gene in the Ensembl database and
compared this classiﬁcation to their FIRMA scores. This merely
gave an indication of the performance of the algorithm and clearly
is not equivalent to a true positive rate—just because the region is
known to have a splicing event does not mean that it was spliced
in our samples. Similarly, we could have identiﬁed new splicing
regions not in the database. Moreover, the ‘splicing events’detected
by our automatic scan may be quirks of Ensembl’s clustering of
transcripts into genes and not actual splicing events.
Despite these many caveats, the proportion of splicing calls
that match splicing events in Ensembl is roughly increasing as
a function of our genome-wide score, indicating that the FIRMA
scoresaretrackingrealsplicingevents(FigureS5ainSupplementary
Materials). If we look at just the top 100 probesets from our
genome-wide scan, 70 probesets matched a splicing event in
Ensembl,andthegenome-widescoresforthosethatdidissomewhat
higher than for those that did not (Figure S5b in Supplementary
Materials). If the Ensembl database was complete, we hope for far
more successes in the top hundred probesets. Manually inspecting
the data showed that many of the probesets that did not match an
Ensembl splicing event still have interesting expression patterns,
suggesting that the algorithm has good prospects of utilizing the
Human Exon array to ﬁnd new splicing events.
4.2.2 Colon cancer data For the colon cancer dataset, Gardina
et al. (2006) performed RT-PCR on 41 genes chosen based on
t-tests of the NI. Roughly, a third were conﬁrmed as cancer-speciﬁc
splicing in the samples. Thirty-six of these probesets could be
uniquely identiﬁed and also matched the probesets we analyzed, 16
of which corresponded to conﬁrmed cancer-speciﬁc splicing based
on the RT-PCR results (i.e. found by RT-PCR to consistently have
a different isoform in the cancer from the normal). Gardina et al.
also performed RT-PCR on nine additional genes reported in the
literature as related to colon cancer. Based on their descriptions,
we identiﬁed 16 probesets from these previously reported genes,
which brought the total number of probesets to 52. This gives a
larger number of validations (and wider range of outcomes) than
the tissue data. Moreover most of the probesets were selected for
further validation based on the same data that we are analyzing.
Because the data consists of paired normal and tumor samples,
we took the pairwise difference of FIRMA scores then calculated
the mean difference per probeset for our all-sample score. We
used the mean rather than the t-statistic because the FIRMA score
is already on a comparable scale across genes—and this scale is
more informative as to the level of splicing relative to the noise
of the gene. See Supplementary Materials for more details of the
implementation.
In Figure 4 we show the paired difference in FIRMA scores for
the set of 52 validation probesets. In bulk, the mean value of the
differenceinFIRMAscoresseparatedthoseprobesetsthatconﬁrmed
to have cancer-speciﬁc splicing from those that were not conﬁrmed.
In Figure 5, we plot these probesets on top of the empirical
cumulative distribution function (cdf) of the mean difference in
FIRMA. Almost all of the probesets are in the extremes of the
distribution, which is not surprising given that they were chosen for
further validation.Again, this plot shows that the conﬁrmed and the
non-conﬁrmed probesets are generally well separated by the mean
difference of FIRMAscores (of roughly 1.5 in absolute value), with
two notable exceptions of the probesets from SLC3A2 and CTTN.
A more precise measure of the success rate of our algorithm
is not really feasible based on just these probesets. The mean
difference in FIRMAvalues nicely separated the conﬁrmed from the
non-conﬁrmed probesets, but the ranks of the conﬁrmed probesets
in a genome-wide comparison ranged widely (from 47 to 1537
excepting SLC3A2 and CTTN). Among the probesets that ranked
higher we ﬁnd promising candidates not selected by Gardina et al.
(2006). Filtering choices dramatically change rankings, making
rankings difﬁcult to evaluate or compare. Our ﬁltering was fairly
conservative, as we tried to not remove the validated probesets;
more aggressive ﬁltering will bring down the ranks of the top
conﬁrmed probesets but at the cost of also removing some of them
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Fig. 4. Paired differences in FIRMA scores (represented by color scale) for
all52oftheprobesetsfromtheRT-PCRexperimentsofGardinaetal.(2006).
The probesets (rows) are grouped according to their characterizations of the
RT-PCR results. Again, the color scale is not equally spaced intervals but
based on the percentiles.
from consideration. This highlights the delicate role of ﬁltering
in reducing the false positive rate at the cost of losing viable
candidates. In fact, Gardina et al. chose the probesets to subject
to further RT-PCR experiments from many different ﬁltering runs,
in addition to a manual review of the data. Ultimately more precise
evaluation of the algorithm and of ﬁltering techniques will require
more validations of high ranking probesets based on FIRMAscores
(or a more complete understanding of the transcriptome for colon
cancer).
As a ﬁnal comparison, we examine the ﬁnal list of top 200
candidateprobesetsofGardinaetal.(2006)(basedontheirpreferred
ﬁltering). Only 10 of the 16 conﬁrmed probesets were contained in
this ﬁnal list. Those 10 probesets ranged from rank 1 to 166 in their
own list (compared to rank 47 to 861 with the mean difference of
FIRMA). Presumably they chose candidates across a wide range
of scores to better evaluate their algorithm; this implies that a
wide range of rankings for these probesets is not surprising. Five
non-conﬁrmed probesets were also intermingled in their list of top
200 (with ranks ranging from 7 to 121). In comparison, the mean
difference of FIRMA scores widely separated the conﬁrmed and
non-conﬁrmed probesets (the best rank of the ﬁve non-conﬁrmed
probesets was 2112). However, with only 15 total probesets in
which we can strictly compare the results (all of which were chosen
on the basis of their algorithm and very differing ﬁltering), we
cannot draw any general conclusion regarding the relative behavior
of the algorithms. In fact, much of the difference we see may
Fig. 5. Empirical cdf of the mean difference of the FIRMA scores for
the colon cancer dataset. Superimposed on the plot are the 36 probesets
chosen for further validation by Gardina et al. (2006); these points are color
coded according to the reported RT-PCR results. Points outlined in black are
probesets that are also among their ﬁnal list of top 200 probesets. Below
the plot, noted with line segments, are the scores of the probesets previously
reported in the literature and also tested by RT-PCR by Gardina et al. The
rank of a few of the conﬁrmed probesets are marked; in parenthesis is the
rank amongst only positive (enriched) or negative (reduced) values.
be due to different normalization and summarization choices (see
Supplementary Materials for more details).
5 DISCUSSION
It is anticipated that many researchers will be interested in genome-
wide studies of alternative splicing under particular conditions.
In such cases, a method of ranking genes by evidence of splice
variation is needed. We have reported a method, FIRMA, for
detecting alternatively spliced exons in individual samples, without
replication, from GeneChip Human Exon 1.0 ST data. We have
demonstrated that our method also shows promise in application to
real data. It is able to detect known alternatively spliced exons in
single samples in complex datasets. We also provide software in an
R package to allow general analysis of the array as well as calculate
our FIRMA scores.
Our studies so far have not taken into account the fact that
in some probesets, some or all probes overlap in sequence. This
will occur any time a probeset is designed against a small exon.
Overlapping probes introduce additional correlation which may bias
alternative splicing detection. The problem is confounded if the
overlapping region contains a SNP, for then variability due to the
SNP can be identiﬁed as alternative splicing (Kwan et al., 2007).
Probes containing SNPs could be manually ﬁltered out before ﬁtting
the RMA model, but this indicates the problem that overlapping
probes create. Additionally, a probe may have a high residual not
because it is in an alternatively spliced exon, but because it is poorly
performing (either unresponsive, or hyper–responsive due to strong
cross-hybridization).
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As noted above the problem becomes much more complicated
for all of the algorithms when all the probes in a probeset are
unresponsive. This is often a problem of annotation—the probeset
queries either an intronic region or a non-transcribed region of
the genome. From the point of view of the models of alternative
splicing, there is little to separate such behavior from legitimate
alternative splicing. This can be a problem even when the analysis
is limited to probesets with strong annotation support. If the analysis
expands to ﬁnd truly novel patterns of expression and therefore
includes many more speculative probesets, this problem can be
overwhelming and post-ﬁltering of probesets would be insufﬁcient
(see Supplementary Materials for discussion). We are currently
investigating ways to ﬁlter such completely non-responding probes
to give a more coherent framework for analysis.
So far, we have not addressed the issue of determining a threshold
for alternative splicing discovery in real data. The threshold for
calling an exon alternatively spliced is also not obvious. If we
assume the residuals from ﬁtting the standard model in (1) have a
normal distribution, the null distribution (in the absence of splicing)
of the median of the residuals could be calculated explicitly and
form the basis of a cutoff. However, the distribution of the median
of less than four observations will be sensitive to the assumption of
normality. In a genome-wide study, it will probably be necessary to
derive a threshold empirically, for example by estimating the null
hypothesis as in Efron (2004) or by using control genes. Our future
work will address these issues.
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